NasdaqGM - Nasdaq Real Time Price USD

Atai Life Sciences N.V. (ATAI)

2.2000
+0.1400
+(6.80%)
As of 1:11:17 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,863
308
314
233
20,376
Operating Expense
100,491
102,474
123,340
144,663
140,701
Operating Income
-98,628
-102,166
-123,026
-144,430
-120,325
Net Non Operating Interest Income Expense
-2,680
-2,346
-809
-375
205
Other Income Expense
-47,725
-43,893
84,549
9,623
-16,481
Pretax Income
-149,033
-148,405
-39,286
-135,182
-136,601
Tax Provision
-196
-356
1,016
6,229
-3,989
Earnings from Equity Interest Net of Tax
-299
-2,000
-3,593
-16,006
-41,632
Net Income Common Stockholders
-148,987
-149,269
-40,224
-152,385
-167,808
Diluted NI Available to Com Stockholders
-148,987
-149,269
-40,224
-152,385
-167,808
Basic EPS
-0.91
-0.93
-0.25
-0.98
-1.21
Diluted EPS
-0.91
-0.93
-0.25
-0.98
-1.21
Basic Average Shares
164,505.0100
160,159.9830
158,833.7850
155,719.5850
138,265.8590
Diluted Average Shares
164,505.0100
160,159.9830
158,833.7850
155,719.5850
138,265.8590
Total Operating Income as Reported
-98,976
-102,691
-125,471
-144,787
-135,805
Total Expenses
100,491
102,474
123,340
144,663
140,701
Net Income from Continuing & Discontinued Operation
-148,987
-149,269
-40,224
-152,385
-167,808
Normalized Income
-101,803.1353
-105,964.1816
-112,251.3000
-160,980.2000
-152,590.7100
Interest Income
657
778
1,847
548
205
Interest Expense
3,337
3,124
2,656
923
--
Net Interest Income
-2,680
-2,346
-809
-375
205
EBIT
-145,696
-145,281
-36,630
-134,259
-120,325
EBITDA
-145,090
-144,808
-36,311
-134,091
-120,278
Reconciled Depreciation
606
473
319
168
47
Net Income from Continuing Operation Net Minority Interest
-148,987
-149,269
-40,224
-152,385
-167,808
Total Unusual Items Excluding Goodwill
-47,246
-43,409
84,738
10,112
-15,675
Total Unusual Items
-47,246
-43,409
84,738
10,112
-15,675
Normalized EBITDA
-97,844
-101,399
-121,049
-144,203
-104,603
Tax Rate for Calcs
0
0
0.0002
0.0002
0
Tax Effect of Unusual Items
-62.1353
-104.1816
12,710.7000
1,516.8000
-457.7100
12/31/2021 - 6/18/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CYBN Cybin Inc.
7.82
+4.70%
 
MNMD Mind Medicine (MindMed) Inc.
7.27
-0.48%
 
GHRS GH Research PLC
11.85
+6.09%
 
CYBN.NE Cybin Inc.
10.78
-0.65%
 
ATYR aTyr Pharma, Inc.
3.8850
+3.60%
 
RIGL Rigel Pharmaceuticals, Inc.
19.40
+2.37%
 
VIGL Vigil Neuroscience, Inc.
7.89
-0.06%
 
SLS SELLAS Life Sciences Group, Inc.
1.9450
+2.91%
 
HUMA Humacyte, Inc.
2.4950
-1.39%
 
CMND Clearmind Medicine Inc.
0.9750
+1.24%